Avidor, Y., Mabjeesh, N. et Matzkin, H. Biotechnology and Drug Discovery: From Bench to Bedside. Southern Medical Journal, 2003, Vol. 96, No.12.
Boehncke, W.H. et Radeke H.H. (Eds.) Biologics in General Medicine, Springer-Verlag Berlin Heidelberg New York, 2007, 190 pp.
Calvo, B. et Zuñiga, L. EU`s New Pharmacovigilance Legislation: Considerations for Biosimilars. Drug Safety. 2014, Vol. 37, pp. 9-18
Chow, S.C. et Ch. Ju. Assessing biosimilarity and interchangeability of biosimilar products under the Biologics Price Competition and Innovation Act. Generics and Biosimilars Initiative Journal (GaBI Journal). 2013, Vol. 2. No.1, pp. 20-5.
Ciftci, K. Biosimilars or Follow-on Biologics: Scientific and Regulatory Considerations. ICON Insight. 2010, Vol. 18, pp. 1-5
Dalgaard, K., Evers, M. et Santos da Silva, J. Biosimilars seven years on: Where are we and what`s next? Insights into Pharmaceutical and Medical Products. McKinsey & Company, 2012
Dudzinski, D. Reflections on Historical, Scientific, and Legal Issues Relevant to Designing Approval Pathways for Generic Versions of Recombinant Protein - based Therapeutics and Monoclonal Antibodies. Food and Drug Law Journal, 2005, pp. 2-3.
Editorial. Tighter EU rules on pharmacovigilance for biologicals. Generics and Biosimilars Initiative Journal (GaBI Journal). 2012, Vol. 1, No. 2, pp. 567.
EuropaBio. Guide to Biological Medicines. A Focus on Biosimilar Medicines. EuropaBio. [Online] October 26, 2011. via http://www.europabio.org/guide-biological-medicines-focus-biosimilar-medicines.
Fox, A. Biosimilar medicines - New challenges for a new class of medicine. J Biopharm Stat. 2010, Vol. 20, No.1, pp. 3-9.
Gamerman, G.E. Regulation of Biologics Manufacturing: Questioning the Premise. Food and Drug Law Journal, 1994, vol. 49, pp. 218.
Grabowski, H, Cockburn, I. et Long, G. The Market for Follow - on Biologics: How Will it Evolve?`Health Affairs, Vol. 25, No. 5, September/October 2006, p. 1299.
Herrera, S. Biogenerics Standoff, Nature Biotechnology, Vol. 22, No. 11, Nov. 2004, p. 1345.
Horton, L.R. The European Experience With Follow-on Biologics Legislation, Federal Trade Commission Roundtable on Follow-on Biologic Drugs: Framework for Competition and Continued Innovation, 2008
Kaldre, I. The future of generic biologics: Should the United States `follow-on` the European pathway? Duke Law & Technology Review 2008; 9:5-18
Kingham, R., Klasa, G. et Carver, K.H. Key Regulatory Guidelines for the Development of Biologics in the United States and Europe. In: Biological Drug Products: Development and Strategies, First Edition. Edited by Wei Wang and Manmohan Singh. 2014 John Wiley & Sons, Inc.
McCamish, M. et Woollett, G. The state of the art in the development of biosimilars. Clin Pharmacol Ther 2012; 91(3): 405-417.
Roger, S.D. et Mikhail, A. Biosimilars: opportunity or cause for concern?. J Pharm Pharm Sci. 2007, Vol. 10, No. 3, pp. 405-10
Schellekens, H., `When biotech proteins go off - patent,` Trends in Biotechnology. 2004, Vol. 22, No. 8, pp. 407.
van Regenmortel, M.H., Boven, K. et Bader, F. Immunogenicity of Biopharmaceuticals: An Example from Erythropoietin. BioPharm International, August 1, 2005, accessed via http://www.biopharminternational.com
European Commission Consensus Information Paper 2013. What you need to know about Biosimilar Medicinal Products
GaBI Online Generics and Biosimilars Initiative. What happened in biosimilars during 2014 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International. Available from: http://www.gabionline.net/Biosimilars/General/What-happened-in-biosimilars-during-2014
IMS Institute for Healthcare Informatics. Assessing biosimilar uptake and competition in European markets. October 2014
http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Questions_Answers/CMDh_321_2014_Rev01_2014_10.pdf
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000330.jsp &mid=WC0b01ac058002956b#ComparabilityBiosimilarity
Email this article (Login required) 
